Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

L-Arginine and Improved Quality of Life

Research synthesisLow evidenceMixed effect size4 studies · 3 beneficial · 1 neutral · 0 harmful

Across 4 studies, 3 reported beneficial effects and 1 found neutral results, with effect sizes ranging from small to large. The evidence suggests L-arginine may improve quality of life in clinical populations, particularly in patients with COPD, head and neck cancer, and PCOS, typically over 4–26 weeks. The most commonly studied dose was 1.66 g twice daily to 5 g daily, but dose reporting was inconsistent.

  • Effective dose range: 1.66 g twice daily to 5 g daily
  • Studied populations: patients with COPD, head and neck cancer with radiation-induced oral mucositis, and females with PCOS

Caveats: Evidence base is small (only 4 studies) — conclusions should be considered preliminary. Available evidence is overwhelmingly positive — clinical literature in this area is subject to publication bias (null-result studies are less likely to be published or indexed). One study included L-arginine as part of a combination intervention, making it difficult to isolate the effect of L-arginine alone.

Generated Jul 14, 2026
Doses used in studies
  • g/day: 1.66–5 (median 3.33, IQR 2.5–4.17) — 2 studies
Time to effect
Median: 7 weeks · IQR 5.5 weeks–3.9 months · Range 4 weeks–6.1 months — Reported in 3 of 4 studies
Safety in these studies
4 of 4 papers
Back to top